Pharmaceutical, cellular and genetic therapies for Huntington's disease
| Autor: | Anne Elizabeth Rosser, Stephen B. Dunnett, Jenny J. Naji, Olivia J. Handley |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Pathology
medicine.medical_specialty Genetic enhancement Disease Bioinformatics Cell therapy Degenerative disease Huntington's disease Fetal Tissue Transplantation medicine Huntingtin Protein Animals Humans Clinical Trials as Topic business.industry Neurodegeneration Genetic Therapy General Medicine medicine.disease Corpus Striatum Clinical trial Disease Models Animal Huntington Disease Neuroprotective Agents Gene Targeting business |
| Zdroj: | Clinical Science. 110:73-88 |
| ISSN: | 1470-8736 0143-5221 |
| DOI: | 10.1042/cs20050148 |
| Popis: | HD (Huntington's disease) is a devastating neurodegenerative disorder caused by a polyglutamine expansion in the gene encoding the huntingtin protein. Presently, there is no known cure for HD and existing symptomatic treatments are limited. However, recent advances have identified multiple pathological mechanisms involved in HD, some of which have now become the focus of therapeutic intervention. In this review, we consider progress made towards developing safe and effective pharmaceutical-, cell- and genetic-based therapies, and discuss the extent to which some of these therapies have been successfully translated into clinical trials. These new prospects offer hope for delaying and possibly halting this debilitating disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|